[Infostock Daily= Reporter An Hoe Hyun] Samsung Biologics is working with Kanaph Therapeutics to develop treatments for retinal diseases.
Samsung Biologics made an announcement on the 24th that it has signed a contract for consigned development(CDO) with Kanaph Therapeutics to support the entire process of developing new drugs, including cell-based development, process development, nonclinical and clinical samples for the retinal diseases treatment(KNP-301).
KNP-301, a new substance of Kanaph, is a double fusion protein that is an indication for dry macular degeneration and diabetic retinopathy, which are retinal diseases.
Reporter An Hoe Hyun ahh@infostock.co.kr
저작권자 © 인포스탁데일리 무단전재 및 재배포 금지
